Comparative Pharmacology
Head-to-head clinical analysis: ETHMOZINE versus MULTAQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHMOZINE versus MULTAQ.
ETHMOZINE vs MULTAQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ic antiarrhythmic; blocks cardiac sodium channels, slowing phase 0 depolarization and reducing conduction velocity in atrial and ventricular myocardium.
Dronedarone is a multichannel blocker that inhibits potassium currents (IKr, IKs, IK-ACh), sodium current (INa), and L-type calcium current (ICaL), and has antiadrenergic properties via noncompetitive blockade of beta-adrenergic receptors.
200-300 mg orally every 8 hours; maximum 900 mg/day.
400 mg orally twice daily with morning and evening meals.
None Documented
None Documented
3-12 hours (mean ~6 hours); prolonged in hepatic or renal impairment.
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) after oral administration, allowing for twice-daily dosing.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for <1% of a dose; approximately 10-20% excreted in feces via bile.
Primarily fecal (84%) after biliary excretion; renal excretion accounts for <6% as unchanged drug and metabolites.
Category C
Category C
Antiarrhythmic
Antiarrhythmic